Patients Need Wound Care.
We Need Your Help.
Now is the time to act to prevent CMS from reducing access to clinically-proven wound care products.
Medicare’s decisions could limit access to clinically proven wound care products and hinder providers’ ability to sustain their practices.
Use the buttons below to contact your elected officials or share your wound care story to help protect access to these vital products and clinics.
BACKGROUND
Medicare has long covered “skin substitutes”, products derived primarily from donated human tissue, that are clinically proven to treat persistent, painful chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure injuries.
On April 25, 2024, all Medicare Administrative Contractors (MACs), the private companies that manage the Medicare program, released nearly identical proposed policies that would eliminate coverage for most skin substitute products and severely restrict the use of the few that remain.
On July 16, 2025 CMS issued its proposed Physician Fee Schedule for 2026, which proposed to dramatically reduce the reimbursement available for skin substitutes. The unprecedented proposed reduction in reimbursement for office and mobile-based wound providers puts patient access to skin substitutes and other advanced wound care under direct threat.
If the proposed policies are finalized, 90% of these effective products that are currently in high use, would no longer be accessible, and many providers will be unable to afford to continue to provide skin substitutes for their patients at all. This will lead to significant shortages of skin substitute products for seniors and other underserved patients with serious, painful wounds, which will lead to increased risk of sepsis, amputation and death.
Ready to act to help keep these products available to the patients who need them?